A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the safety and recommended dose level (RDL)
of BLEX 404 Oral Liquid combined with Gemcitabine monotherapy in a 28-day schedule.The
secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with
Gemcitabine monotherapy at the recommended dose.